Clinical trials
High-Risk Cancer clinical trials
Below are recruiting high-risk cancer clinical trials, each written for real people, not researchers. We’re tracking 396 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07792993Recruiting
Focused radiation boost for intermediate and high-risk prostate cancer
This trial tests whether adding an extra, targeted dose of radiation to the main tumor during standard radiation therapy can better control prostate cancer. It is for patients with intermediate or high-risk prostate cancer that has not spread, and who are eligible for a shorter course of radiation (20 sessions).
Rome, LazioAges 18–99 - NCT07054346RecruitingPhase 1
Radioactive drugs before prostate surgery for high-risk prostate cancer
This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.
San Francisco, CaliforniaAges 18 years+ - NCT07784387Recruiting
Bladder cancer study in Portugal
This study looks at the characteristics and outcomes of people with high-risk non-muscle-invasive bladder cancer in Portugal. It aims to understand the disease better and could help improve future treatments.
LisbonAges 18 years+ - NCT07071961RecruitingPhase 2
Treatment for colorectal cancer with signs of remaining disease after therapy
This trial tests a combination of two drugs, regorafenib and lorigerlimab, for people with colorectal cancer that has a positive blood test for cancer DNA after they have finished standard treatments. The goal is to see if this treatment can delay or prevent the cancer from coming back.
Houston, TexasAges 18 years+ - NCT07061977RecruitingPhase 3
New cancer drug combo for advanced cervical cancer
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
Birmingham, AlabamaAges 18 years+ - NCT06482073Recruiting
Genetic testing for suspected lung cancer
This study looks at genetic changes in people with suspected or high-risk lung cancer. It aims to use those results to guide more personalized treatment decisions.
Rochester, MinnesotaAges 18 years+ - NCT06628570Recruiting
Screening methods for anal cancer in high-risk adults
This study is looking at ways to screen for anal cancer in people who are at higher risk, such as those with weakened immune systems or a history of abnormal cells in the lower genital tract. It aims to find better methods for early detection.
Miami, FloridaAges 30–80 - NCT05593497RecruitingPhase 2
Combination therapy before prostate surgery for high-risk prostate cancer
This study tests a combination of hormone therapy and a targeted drug before prostate surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach can improve outcomes.
West Los Angeles, CaliforniaAges 18 years+ - NCT07779109Recruiting
Shorter radiation course for endometrial cancer after surgery
This study tests a shorter, more intense course of radiation therapy after surgery for endometrial cancer. It aims to see if it is safe and works as well as standard radiation, while possibly reducing treatment time.
Zaragoza, ZaragozaAges 18–110 - NCT06952803RecruitingPhase 3
Testing a new drug for men with BRCA-related prostate cancer
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
Phoenix, ArizonaAges 18 years+ - NCT05463796Recruiting
Prevention and early detection for people at high cancer risk
This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.
Boston, MassachusettsAges Any age - NCT07549321RecruitingPhase 2/Phase 3
Hu14 Immunotherapy for High-Risk Neuroblastoma in Children
This study tests a new antibody-based immunotherapy called hu14 for children and young adults with high-risk neuroblastoma (an aggressive childhood cancer that has spread). The treatment is designed to help the immune system fight cancer cells.
Aurora, ColoradoAges 1.5 years–18 years - NCT07763197Recruiting
Sample collection for bladder cancer research
This study is collecting blood, urine, and tissue samples from people with high-risk non-muscle invasive bladder cancer to help develop better tests for tracking the disease. By participating, you might help improve future monitoring and treatment decisions.
Austin, TexasAges 18 years+ - NCT07751159RecruitingPhase 2
Comparing radiation therapy methods for prostate cancer
This study compares two types of radiation therapy for prostate cancer that hasn't spread. It aims to find which approach is more effective and has fewer side effects.
Basking Ridge, New JerseyAges Any age - NCT07450599RecruitingPhase 2
Darolutamide plus hormone therapy before prostate cancer surgery
This trial tests a medicine called darolutamide taken with hormone therapy (ADT) before surgery to remove the prostate. It is for men with a high-risk prostate cancer that has not spread to other parts of the body.
Hefei, AnhuiAges 18 years+ - NCT07242352RecruitingPhase 3
Comparing elacestrant to standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
Mannheim, Baden-WurttembergAges 18 years+ - NCT07483970RecruitingPhase 1
JL19001 alone or with BCG for high-risk non-muscle invasive bladder cancer
This trial tests a new drug called JL19001, given alone or with BCG (a standard bladder cancer treatment), for people with high-risk bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help prevent the cancer from coming back or getting worse.
Chengdu, SichuanAges 18 years+ - NCT07455903RecruitingPhase 2
Hormone therapy before surgery for high-risk prostate cancer
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
Miami, FloridaAges 18 years+ - NCT06791161Enrolling by invitation
Adjuvant therapy study for BRCA1/2 positive breast cancer
This study tests if additional treatment after surgery helps prevent breast cancer from returning. It is for people with hormone receptor-positive, HER2-negative breast cancer who have a BRCA1 or BRCA2 gene mutation and a high risk of recurrence.
Beijing, Beijing MunicipalityAges 18–75 - NCT06461793RecruitingPhase 2
Higher dose radiation with hormone therapy for high-risk prostate cancer
This trial tests a higher dose of radiation given in fewer sessions (hypofractionated) combined with hormone therapy for men with high-risk prostate cancer that has not spread. A gel spacer called SpaceOAR is used to protect the rectum. The goal is to see if this approach is safe and effective.
SeoulAges 20 years+ - NCT06378242RecruitingPhase 1/Phase 2
Testing a bladder cancer drug for high-risk NMIBC patients
This trial tests a drug called Disitamab Vedotin, given directly into the bladder, for a type of early bladder cancer (high-risk NMIBC) that has a protein called HER2. It aims to see if this treatment can help avoid more radical surgery.
Guangzhou, GuangdongAges 18–75 - NCT05834764RecruitingPhase 2
Pyrotinib for high-risk HER2-positive early breast cancer
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
Nanjing, JiangsuAges 18–75 - NCT04221035RecruitingPhase 3
Trial for children with high-risk neuroblastoma testing next steps
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
Sydney, RandwickAges Up to 21 years - NCT05852223RecruitingPhase 2
Pembrolizumab for high-risk thyroid cancer that cannot be fully removed
This study tests pembrolizumab (an immune therapy) in people with high-risk thyroid cancer that is hard to treat with surgery alone. It looks at whether this drug can reduce persistent or recurrent cancer after your planned treatment.
Pavia, LombardyAges 18 years+
Hear when a new High-Risk Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high-risk cancer?
- Yes. Clin2 currently lists 396 recruiting high-risk cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high-risk cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high-risk cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.